肿瘤科

订阅

MedSci主页 / 所有栏目 / 肿瘤科

CLIN CANCER RES：叶酸受体抗原肽疫苗在乳腺癌和卵巢癌患者中可以诱导免疫

2018-07-02 MedSci MedSci原创

叶酸受体乳腺癌卵巢癌免疫
关注

叶酸受体（FR）在几种肿瘤中过表达。在患者中发现了针对叶酸受体的内源性免疫，使得通过疫苗或其他免疫治疗靶向叶酸受体成为可能。CD4辅助性T细胞在免疫发展过程中至关重要，之前的研究证实其在预防复发方面有重要意义。来源于人叶酸受体的HLA-Ⅱ类表位可以诱导出覆盖范围较大的抗原表位池，在增强抗原特异性免疫反应方面均有潜在意义。CLIN CANCER RES近期发表了一篇文章，对这一问题进行研究。

叶酸受体（FR）在几种肿瘤中过表达。在患者中发现了针对叶酸受体的内源性免疫，使得通过疫苗或其他免疫治疗靶向叶酸受体成为可能。CD4辅助性T细胞在免疫发展过程中至关重要，之前的研究证实其在预防复发方面有重要意义。来源于人叶酸受体的HLA-Ⅱ类表位可以诱导出覆盖范围较大的抗原表位池，在增强抗原特异性免疫反应方面均有潜在意义。CLIN CANCER RES近期发表了一篇文章，对这一问题进行研究。

作者进行了Ⅰ期临床试验验证这一疫苗的安全性和免疫原性，研究纳入的患者为完成了常规治疗的卵巢癌或乳腺癌患者。患者初始接受低剂量的环磷酰胺治疗，然后接受6次疫苗治疗，每个月一次。在接受疫苗期间及1年后检测其免疫及安全性。研究结果表明，疫苗在所有患者中均耐受良好。疫苗在超过90%的患者中会增强免疫。叶酸受体T细胞反应在疫苗治疗期间逐渐发展，中位时间5个月时达到最强的免疫效果。尽管免疫效果发展较慢，但是反应持续时间至少为12个月。

文章最后认为，增强靶向叶酸受体肿瘤抗原的免疫是安全的，已研究出的疫苗在绝大部分肿瘤表达叶酸受体的患者中均有治疗效果。

原始出处：
Kimberly R.Kalli,Matthew S.Block,et al.Folate Receptor Alpha Peptide Vaccine Generates Immunity in Breast and Ovarian Cancer Patients.CLIN CANCER RES.July 2018 doi:10.1158/1078-0432.CCR-17-2499

本文系梅斯医学（MedSci）原创编译整理，转载需授权！

版权声明：
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料，版权均属于梅斯医学所有。非经授权，任何媒体、网站或个人不得转载，授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章，或“梅斯号”自媒体发布的文章，仅系出于传递更多信息之目的，本站仅负责审核内容合规，其内容不代表本站立场，本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系，我们将立即进行删除处理。
在此留言
评论区 (4)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1797788, encodeId=9c691e977883a, content=<a href='/topic/show?id=32fc23e41e3' target=_blank style='color:#2F92EE;'>#乳腺癌和卵巢癌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=23741, encryptionId=32fc23e41e3, topicName=乳腺癌和卵巢癌)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8b48400, createdName=rgjl, createdTime=Fri Jan 04 14:41:00 CST 2019, time=2019-01-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2060902, encodeId=fb5e206090234, content=<a href='/topic/show?id=4bff38e05e6' target=_blank style='color:#2F92EE;'>#叶酸受体#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=38705, encryptionId=4bff38e05e6, topicName=叶酸受体)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8949377, createdName=chenzhuanggui, createdTime=Fri Jan 25 01:41:00 CST 2019, time=2019-01-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1623297, encodeId=b090162329ea0, content=<a href='/topic/show?id=62a655263e9' target=_blank style='color:#2F92EE;'>#抗原#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=55263, encryptionId=62a655263e9, topicName=抗原)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f59b20519025, createdName=xiaoyeshuang, createdTime=Wed Jul 04 10:41:00 CST 2018, time=2018-07-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=328913, encodeId=ef2f32891320, content=了解一下谢谢, beContent=null, objectType=article, channel=null, level=null, likeNumber=74, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTLbTp9nZtjwVrSZNxAXbAicnKQWnic2eBdJUQYhxO36XdkstSicr7FVF8p5ReH4omtmsbnLdvZLiaJJ1A/132, createdBy=8bff2327056, createdName=kafei, createdTime=Tue Jul 03 07:43:36 CST 2018, time=2018-07-03, status=1, ipAttribution=)]
    2019-01-04 rgjl

    #乳腺癌和卵巢癌#

    0

  2. [GetPortalCommentsPageByObjectIdResponse(id=1797788, encodeId=9c691e977883a, content=<a href='/topic/show?id=32fc23e41e3' target=_blank style='color:#2F92EE;'>#乳腺癌和卵巢癌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=23741, encryptionId=32fc23e41e3, topicName=乳腺癌和卵巢癌)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8b48400, createdName=rgjl, createdTime=Fri Jan 04 14:41:00 CST 2019, time=2019-01-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2060902, encodeId=fb5e206090234, content=<a href='/topic/show?id=4bff38e05e6' target=_blank style='color:#2F92EE;'>#叶酸受体#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=38705, encryptionId=4bff38e05e6, topicName=叶酸受体)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8949377, createdName=chenzhuanggui, createdTime=Fri Jan 25 01:41:00 CST 2019, time=2019-01-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1623297, encodeId=b090162329ea0, content=<a href='/topic/show?id=62a655263e9' target=_blank style='color:#2F92EE;'>#抗原#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=55263, encryptionId=62a655263e9, topicName=抗原)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f59b20519025, createdName=xiaoyeshuang, createdTime=Wed Jul 04 10:41:00 CST 2018, time=2018-07-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=328913, encodeId=ef2f32891320, content=了解一下谢谢, beContent=null, objectType=article, channel=null, level=null, likeNumber=74, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTLbTp9nZtjwVrSZNxAXbAicnKQWnic2eBdJUQYhxO36XdkstSicr7FVF8p5ReH4omtmsbnLdvZLiaJJ1A/132, createdBy=8bff2327056, createdName=kafei, createdTime=Tue Jul 03 07:43:36 CST 2018, time=2018-07-03, status=1, ipAttribution=)]
    2019-01-25 chenzhuanggui

    #叶酸受体#

    0

  3. [GetPortalCommentsPageByObjectIdResponse(id=1797788, encodeId=9c691e977883a, content=<a href='/topic/show?id=32fc23e41e3' target=_blank style='color:#2F92EE;'>#乳腺癌和卵巢癌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=23741, encryptionId=32fc23e41e3, topicName=乳腺癌和卵巢癌)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8b48400, createdName=rgjl, createdTime=Fri Jan 04 14:41:00 CST 2019, time=2019-01-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2060902, encodeId=fb5e206090234, content=<a href='/topic/show?id=4bff38e05e6' target=_blank style='color:#2F92EE;'>#叶酸受体#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=38705, encryptionId=4bff38e05e6, topicName=叶酸受体)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8949377, createdName=chenzhuanggui, createdTime=Fri Jan 25 01:41:00 CST 2019, time=2019-01-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1623297, encodeId=b090162329ea0, content=<a href='/topic/show?id=62a655263e9' target=_blank style='color:#2F92EE;'>#抗原#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=55263, encryptionId=62a655263e9, topicName=抗原)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f59b20519025, createdName=xiaoyeshuang, createdTime=Wed Jul 04 10:41:00 CST 2018, time=2018-07-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=328913, encodeId=ef2f32891320, content=了解一下谢谢, beContent=null, objectType=article, channel=null, level=null, likeNumber=74, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTLbTp9nZtjwVrSZNxAXbAicnKQWnic2eBdJUQYhxO36XdkstSicr7FVF8p5ReH4omtmsbnLdvZLiaJJ1A/132, createdBy=8bff2327056, createdName=kafei, createdTime=Tue Jul 03 07:43:36 CST 2018, time=2018-07-03, status=1, ipAttribution=)]
    2018-07-04 xiaoyeshuang

    #抗原#

    0

  4. [GetPortalCommentsPageByObjectIdResponse(id=1797788, encodeId=9c691e977883a, content=<a href='/topic/show?id=32fc23e41e3' target=_blank style='color:#2F92EE;'>#乳腺癌和卵巢癌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=23741, encryptionId=32fc23e41e3, topicName=乳腺癌和卵巢癌)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8b48400, createdName=rgjl, createdTime=Fri Jan 04 14:41:00 CST 2019, time=2019-01-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2060902, encodeId=fb5e206090234, content=<a href='/topic/show?id=4bff38e05e6' target=_blank style='color:#2F92EE;'>#叶酸受体#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=38705, encryptionId=4bff38e05e6, topicName=叶酸受体)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8949377, createdName=chenzhuanggui, createdTime=Fri Jan 25 01:41:00 CST 2019, time=2019-01-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1623297, encodeId=b090162329ea0, content=<a href='/topic/show?id=62a655263e9' target=_blank style='color:#2F92EE;'>#抗原#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=55263, encryptionId=62a655263e9, topicName=抗原)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f59b20519025, createdName=xiaoyeshuang, createdTime=Wed Jul 04 10:41:00 CST 2018, time=2018-07-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=328913, encodeId=ef2f32891320, content=了解一下谢谢, beContent=null, objectType=article, channel=null, level=null, likeNumber=74, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTLbTp9nZtjwVrSZNxAXbAicnKQWnic2eBdJUQYhxO36XdkstSicr7FVF8p5ReH4omtmsbnLdvZLiaJJ1A/132, createdBy=8bff2327056, createdName=kafei, createdTime=Tue Jul 03 07:43:36 CST 2018, time=2018-07-03, status=1, ipAttribution=)]
    2018-07-03 kafei

    了解一下谢谢

    0